Sensus Healthcare, Inc.
3.2100-0.06 (-1.83%)
Oct 29, 4:00:00 PM EDT · NasdaqCM · SRTS · USD
Key Stats
Market Cap
52.77MP/E (TTM)
-Basic EPS (TTM)
-0.05Dividend Yield
0%Recent Filings
10-Q
Q2 FY2025 results
Sensus Healthcare's Q2 FY2025 revenues fell 20.7% y/y to $7.3M, driven by fewer units sold to its key U.S. customer (63% of H1 sales), while gross margin contracted to 39.7% from 58.7% amid higher servicing costs and a new placement program. Operating expenses climbed 40.9% y/y to $4.8M, fueled by R&D investments in next-gen systems and marketing pushes, yielding an operating loss of $1.9M versus $2.0M profit last year; net loss hit $1.0M or $(0.06) per diluted share, with anti-dilution excluding potential shares due to the loss. Cash held steady at $22.2M, bolstered by $0.4M operating cash flow (derived) and $15M revolver availability under asset-secured covenants, while inventories rose to support future growth. Expenses outpaced revenue. Yet one customer dominates sales.
8-K
Q2 revenues dip to $7.3M
Sensus Healthcare reported Q2 2025 revenues of $7.3 million, down from $9.2 million a year ago due to fewer units sold to a large customer, yet recurring revenue from Fair Deal Agreements grew. The company shipped 19 SRT systems, including four to China, and saw FDA treatment volume rise 27% sequentially, while exiting with $22.2 million in cash and no debt. A proposed Medicare Physician Fee Schedule could boost SRT adoption starting 2026, but mid-quarter reimbursement uncertainty slowed domestic sales. Partnership with ROS targets hospital oncology expansion.
8-K
Annual meeting votes approved
Sensus Healthcare's stockholders, at the May 27, 2025 annual meeting, elected Anthony Petrelli as Class I director for a three-year term, approved amending the 2017 Incentive Plan to extend its term and boost available shares, and gave a non-binding nod to 2024 executive pay. They also ratified Berkowitz Pollack Brant as auditors for fiscal 2025. Petrelli won with 4.3 million for votes, yet faced notable opposition. The plan amendment passed handily, signaling support for talent retention amid growth.
10-Q
Q1 FY2025 results
Sensus Healthcare's Q1 2025 revenues fell 22% year-over-year to $8.3M, driven by fewer units sold to its key U.S. customer, while gross margin slipped to 53.0% from 62.6% amid higher service costs. Operating expenses surged 85% to $7.0M, fueled by R&D outlays for billing code lobbying and product development, plus elevated selling and G&A costs from headcount growth and professional fees, flipping operations to a $2.6M loss from $2.9M profit. Diluted EPS landed at -$0.16 on 16.3M shares, with anti-dilution excluding restricted stock awards. Cash dipped to $19.1M after $2.7M operating outflow, yet $15M revolver availability bolsters liquidity sans debt. Expenses ballooned. Regulatory hurdles in Medicare billing loom as a key risk.
8-K
Q1 revenues drop to $8.3M
Sensus Healthcare reported Q1 2025 revenues of $8.3 million, down from $10.7 million last year due to fewer units sold to a major customer, swinging to a $2.6 million net loss from prior profit. The company shipped 21 SRT systems and saw a 65% jump in treatment volume from its Fair Deal Agreement program. Investments in sales, R&D, and lobbying fueled higher expenses, yet management expects profitability in the next three quarters and full year. Cash stands at $19.1 million.
AIRS
AirSculpt Technologies, Inc.
10.90-0.67
ICCM
IceCure Medical Ltd.
0.75-0.02
LNSR
LENSAR, Inc.
11.90+0.03
NNOX
NANO-X IMAGING LTD
3.74-0.15
RTGN
RETINALGENIX TECHNOLOGIES INC
3.75+0.00
RXST
RxSight, Inc.
8.43-0.38
SENS
Senseonics Holdings, Inc.
7.25+0.05
SNWV
SANUWAVE Health, Inc.
30.44-0.60
SSKN
Strata Skin Sciences, Inc.
1.74-0.19
VERO
Venus Concept Inc.
2.18+0.05